Donor lymphocyte infusion (DLI) using unstimulated leukapheresis is one of the most
effective treatment strategies for patients with hematological malignancies; its graft-versus-
leukemia effects make it especially effective in chronic myeloid leukemia patients who
relapsed after allogeneic stem cell transplantation (allo-HSCT). However, DLI application is
limited by the development of graft-versus-host disease and aplasia, and thus cannot be
routinely applied for prophylaxis. Therefore, important questions remain to be answered …